Ningbo Shengjian Biopharmaceutical Technology

Ningbo Shengjian Biopharmaceutical Technology is a clinical-stage biotechnology company headquartered in Ningbo, China, specializing in the development of next-generation antibody therapeutics. The company focuses on oncology and immunology, utilizing its internal R&D capabilities to design monoclonal and bispecific antibodies that target immune checkpoints and tumor-associated antigens. Its lead candidate, SJ001, is a PD-L1 inhibitor currently in clinical trials for various solid tumors. Another key program, SJ002, targets Claudin 18.2 for the treatment of gastric and pancreatic cancers. Shengjian Bio is supported by prominent venture capital firms like HighLight Capital and is led by a team with extensive experience in global pharmaceutical development. The company aims to address unmet medical needs by providing innovative and accessible biologic treatments.